We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · April 03, 2021

Pathological Response, Tumour Bed Histopathology, and Survival in Neoadjuvant Immunotherapy–Treated Stage III Melanoma

Annals of Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

Annals of Oncology
Pathological Response and Tumour Bed Histopathological Features Correlate With Survival Following Neoadjuvant Immunotherapy in Stage III Melanoma
Ann. Oncol 2021 Mar 17;[EPub Ahead of Print], RV Rawson, C Adhikari, C Bierman, S Lo, E Shklovskaya, EA Rozeman, AM Menzies, ACJ van Akkooi, KF Shannon, M Gonzalez M, AD Guminski, MT Tetzlaff, JR Stretch, H Eriksson, JV van Thienen, MW Wouters, JBAG Haanen, WMC Klop, CL Zuur, WJ van Houdt, OE Nieweg, S Ch’ng, H Rizos, RPM Saw, AJ Spillane, JS Wilmott, CU Blank, GV Long, BA van de Wiel, RA Scolyer

Further Reading